Pulmonary Cell News Volume 4.12 | Apr 2 2015

A Multi-Omics Approach Identifies Key Hubs Associated with Cell Type-Specific Responses of Airway Epithelial Cells to Staphylococcal Alpha-Toxin
Researchers compared two human bronchial epithelial cell lines, i.e. Hla-susceptible 16HBE14o- and Hla-resistant S9 cells, by a quantitative multi-omics strategy for a better understanding of Hla-induced cellular programs. [PLoS One] Full Article

Tobacco Smoke Activates Human Papillomavirus 16 p97 Promoter and Cooperates with High-Risk E6/E7 for Oxidative DNA Damage in Lung Cells
Scientists showed that cigarette smoke condensate has the ability to activate the human papillomavirus type 16 p97 promoter by acting on the long control region in lung epithelial cells. [PLoS One] Full Article

Identification of Helicobacter pylori VacA in Human Lung and Its Effects on Lung Cells
Researchers tested the hypothesis that VacA, an exotoxin of H. pylori, a gastric pathogen, was aspirated into the lung and could stimulate secretion of inflammatory cytokines by lung epithelial cells. [Biochem Biophys Res Commun] Abstract

LUNG CANCER

Suberoylanilide Hydroxamic Acid Treatment Reveals Crosstalks among Proteome, Ubiquitylome and Acetylome in Non-Small Cell Lung Cancer A549 Cell Line
By using SILAC technique, antibody-based affinity enrichment and high-resolution LC-MS/MS analysis, scientists investigated quantitative proteome, acetylome and ubiquitylome as well as crosstalks among the three datasets in A549 cells toward suberoylanilide hydroxamic acid treatment. [Sci Rep] Full Article

Functional Role and Mechanism of lncRNA LOC728228 in Malignant 16HBE Cells Transformed by Anti-Benzopyrene-trans-7,8-Dihydrodiol-9,10-Epoxide
Scientists attempted to identify lung-cancer-related long noncoding RNAs (lncRNAs). They found changes in lncRNA expression in the anti-benzo(a) pyrene-7,8-diol-9,10-epoxide-transformed human bronchial epithelial cell line using microarrays and qRT-PCR. [Mol Carcinog] Abstract

Endothelial PAS Domain-Containing Protein 1 Confers TKI-Resistance by Mediating EGFR and MET Pathways in Non-Small Cell Lung Cancer Cells
Researchers report that endothelial PAS domain-containing protein 1, with 48% sequence identity to hypoxia-inducible factor-1α, specifically binds to TKI-resistant T790M epidermal growth factor receptor (EGFR), but not to wild-type EGFR, in non-small-cell lung cancer cell lines. [Cancer Biol Ther] Abstract

Improvement of Anti-Tumor Abilities on Human Non-Small Cell Lung Carcinoma by Micellization and Cross-Linking of N-(2-Hydroxypropyl) Methacrylamide Copolymers
The characteristics of N-(2-hydroxypropyl) methacrylamide micelles were investigated and compared using human non-small cell lung carcinoma 3-D culture model and nude mice xenograft model. Cross-linked micelles showed highest cytotoxicity on A549 cell monolayers after a short time treatment in vitro. [J Drug Target] Abstract

Abnormal Expression of miR-21 and miR-95 in Cancer Stem-Like Cells Is Associated with Radioresistance of Lung Cancer
Scientists demonstrated that miR-21 and miR-95 expression were significantly higher in the ALDH1⁺CD133⁺subpopulation than in the ALDH1^–CD133^– subpopulation of lung cancer cells. [Cancer Invest] Abstract

Visit our reviews page to see a complete list of reviews in the pulmonary cell research field.

From our sponsor:
Looking for ALDH⁺ cancer stem cells? Watch a video to see how ALDEFLUOR™ can help.

Solid Tumor Study Investigating Ibrutinib (IMBRUVICA^®) in Combination with Anti-PD-L1 Antibody (MEDI4736) Commences in Patients with Relapsed/Refractory Non-Small Cell Lung, Breast and Pancreatic Cancers
Pharmacyclics, Inc. announced the initiation of PCYC-1135-CA, a multi-center study that will investigate the use of ibrutinib (IMBRUVICA^®) in combination with MEDI4736. The Phase Ib/II study will examine the safety, tolerability and effectiveness of this investigational combination in individuals with relapsed or refractory non-small cell lung cancer, breast cancer, and pancreatic cancer. [Pharmacyclics, Inc.] Press Release

World Renowned Surgeon Joins VisionGate’s Medical Advisory Board
VisionGate, Inc. announced that nationally renowned thoracic surgeon Dr. Harvey Pass has joined its Medical Advisory Board. Dr. Pass specializes in detecting, diagnosing and treating pleural mesothelioma and lung cancer. [VisionGate, Inc.] Press Release

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the pulmonary cell community.

NEW Research Assistant – Inflammation in the Lung during Viral Infection (Duke-NUS Graduate Medical School Singapore)

Scientist – Pluripotent Stem Cell Biology Endoderm Lineages (STEMCELL Technologies Inc.)

PhD Studentship – Cystic Fibrosis (University of East Anglia)

Postdoctoral Fellowship – Pulmonary Genetic Medicine (Cornell University)

Postdoctoral Researcher – Pulmonary Developmental Pathology (Drexel University College of Medicine)

Postdoctoral Position – Airway Disease and Inflammation (Brigham and Women’s Hospital Harvard Medical School)

PhD Studentship – Mouse Models of Asthma (University of Queensland)

Postdoctoral Scholar – Molecular Mechanisms of Lung Cancer, Lung Regeneration and Lung Development (University of California, San Francisco)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.